International journal of molecular sciences, 2017-09, Vol.18 (10), p.2021
2017
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Angiogenesis Inhibitors in NSCLC
- Ist Teil von
- International journal of molecular sciences, 2017-09, Vol.18 (10), p.2021
- Ort / Verlag
- Switzerland: MDPI AG
- Erscheinungsjahr
- 2017
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy; however, it was limited to patients with non-squamous histology and first-line setting. Approval was based on the results of two phase III trials (ECOG4599 and AVAIL) that demonstrated an improvement of about two months in progression-free survival (PFS) in both trials, and in the ECOG4599 trial, an improvement in overall survival (OS) also. Afterwards, other antiangiogenic agents, including sunitinib, sorafenib, and vandetanib have been unsuccessfully tested in first and successive lines. Recently, two new antiangiogenic agents (ramucirumab and nintedanib) produced a significant survival benefit in second-line setting. In the REVEL study, ramucirumab plus docetaxel prolonged the median OS of patients with any histology NSCLC when compared with docetaxel alone (10.4 versus 9.1 months, hazard ratio (HR) 0.857, = 0.0235). In the LUME-Lung 1 study, nintedanib plus docetaxel prolonged the median PFS of patients with any tumor histology ( = 0.0019), and improved OS (12.6 versus 10.3 months) in patients with adenocarcinoma. As a result, it became a new option for the second-line treatment of patients with advanced NSCLC and adenocarcinoma histology. Identifying predictive biomarkers to optimize the benefit of antiangiogenic drugs remains an ongoing challenge.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1422-0067, 1661-6596eISSN: 1422-0067DOI: 10.3390/ijms18102021Titel-ID: cdi_doaj_primary_oai_doaj_org_article_26be4d44f1404d4eb3e1f6107436e2ba
- Format
- –
- Schlagworte
- Adenocarcinoma, Adenocarcinoma - drug therapy, Adenocarcinoma - metabolism, Adenocarcinoma - mortality, Adenocarcinoma - pathology, Angiogenesis, Angiogenesis inhibitors, Angiogenesis Inhibitors - therapeutic use, Antiangiogenic agents, Antiangiogenics, Antibodies, Monoclonal - therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Bevacizumab, Bevacizumab - therapeutic use, Biological activity, Carcinoma, Non-Small-Cell Lung - drug therapy, Carcinoma, Non-Small-Cell Lung - metabolism, Carcinoma, Non-Small-Cell Lung - mortality, Carcinoma, Non-Small-Cell Lung - pathology, Chemotherapy, Clinical trials, Clinical Trials, Phase III as Topic, Disease-Free Survival, Docetaxel, Histology, Humans, Indoles - therapeutic use, Lung cancer, Lung Neoplasms - drug therapy, Lung Neoplasms - metabolism, Lung Neoplasms - mortality, Lung Neoplasms - pathology, Metastases, Metastasis, Monoclonal antibodies, Neovascularization, Pathologic - drug therapy, Neovascularization, Pathologic - metabolism, Neovascularization, Pathologic - mortality, Neovascularization, Pathologic - pathology, Niacinamide - analogs & derivatives, Niacinamide - therapeutic use, nintedanib, Non-small cell lung carcinoma, Patients, Phenylurea Compounds - therapeutic use, Piperidines - therapeutic use, Pyrroles - therapeutic use, Quinazolines - therapeutic use, Ramucirumab, Review, Sorafenib, Sunitinib, Survival, Targeted cancer therapy, Taxoids - therapeutic use, Tumors, vascular endothelial growth factor (VEGF), VEGF trap